1-19 of 19
Maurizio Scaltriti
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple PIK3CA Mutations

Open Access
Smruthy Sivakumar, Dexter X. Jin, Ruchita Rathod, Jeffrey Ross, Lewis C. Cantley, Maurizio Scaltriti, Jessica W. Chen, Katherine E. Hutchinson, Timothy R. Wilson, Ethan S. Sokol, Neil Vasan
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (6): 1125–1136.
https://doi.org/10.1158/1078-0432.CCR-22-2270
Published: 14 March 2023
View articletitled, Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple PIK3CA Mutations
Open the PDF for Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple PIK3CA Mutations in another window
Includes: Supplementary data
Journal Articles

High FGFR1–4 mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer

Available to Purchase
Mònica Sánchez-Guixé, Cinta Hierro, José Jiménez, Cristina Viaplana, Guillermo Villacampa, Erika Monelli, Fara Brasó-Maristany, Zighereda Ogbah, Mireia Parés, Marta Guzmán, Judit Grueso, Olga Rodríguez, Mafalda Oliveira, Analía Azaro, Elena Garralda, Josep Tabernero, Oriol Casanovas, Maurizio Scaltriti, Aleix Prat, Rodrigo Dienstmann, Paolo Nuciforo, Cristina Saura, Mariona Graupera, Ana Vivancos, Jordi Rodon, Violeta Serra
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (1): 137–149.
https://doi.org/10.1158/1078-0432.CCR-21-1810
Published: 05 January 2022
View articletitled, High FGFR1–4 mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer
Open the PDF for High FGFR1–4 mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers

Available to Purchase
Komal Jhaveri, Matthew T. Chang, Dejan Juric, Cristina Saura, Valentina Gambardella, Anton Melnyk, Manish R. Patel, Vincent Ribrag, Cynthia X. Ma, Raid Aljumaily, Philippe L. Bedard, Jasgit C. Sachdev, Lara Dunn, Helen Won, John Bond, Surai Jones, Heidi M. Savage, Maurizio Scaltriti, Timothy R. Wilson, Michael C. Wei, David M. Hyman
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (2): 447–459.
https://doi.org/10.1158/1078-0432.CCR-20-2657
Published: 19 January 2021
View articletitled, Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers
Open the PDF for Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers in another window
Includes: Supplementary data
Journal Articles

Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer

Free
Lillian M. Smyth, Kenji Tamura, Mafalda Oliveira, Eva M. Ciruelos, Ingrid A. Mayer, Marie-Paule Sablin, Laura Biganzoli, Helen J. Ambrose, Jack Ashton, Alan Barnicle, Des D. Cashell, Claire Corcoran, Elza C. de Bruin, Andrew Foxley, Joana Hauser, Justin P.O. Lindemann, Rhiannon Maudsley, Robert McEwen, Michele Moschetta, Martin Pass, Vicky Rowlands, Gaia Schiavon, Udai Banerji, Maurizio Scaltriti, Barry S. Taylor, Sarat Chandarlapaty, José Baselga, David M. Hyman
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (15): 3947–3957.
https://doi.org/10.1158/1078-0432.CCR-19-3953
Published: 03 August 2020
View articletitled, Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer
Open the PDF for Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts

Free
Albert Gris-Oliver, Marta Palafox, Laia Monserrat, Fara Brasó-Maristany, Andreu Òdena, Mònica Sánchez-Guixé, Yasir H. Ibrahim, Guillermo Villacampa, Judit Grueso, Mireia Parés, Marta Guzmán, Olga Rodríguez, Alejandra Bruna, Caroline S. Hirst, Alan Barnicle, Elza C. de Bruin, Avinash Reddy, Gaia Schiavon, Joaquín Arribas, Gordon B. Mills, Carlos Caldas, Rodrigo Dienstmann, Aleix Prat, Paolo Nuciforo, Pedram Razavi, Maurizio Scaltriti, Nicholas C. Turner, Cristina Saura, Barry R. Davies, Mafalda Oliveira, Violeta Serra
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (14): 3720–3731.
https://doi.org/10.1158/1078-0432.CCR-19-3324
Published: 15 July 2020
View articletitled, Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts
Open the PDF for Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts in another window
Includes: Supplementary data
Journal Articles

Abstract 16: Landscape and outcome of TRK fusion-positive Cancers

Free
Ezra Y. Rosen, Debra A. Goldman, Jaclyn F. Hechtman, Ryma Benayed, Alison M. Schram, Emiliano Cocco, Sophie Shifman, Yixiao Gong, Ritika Kundra, James P. Solomon, Alberto Bardelli, Maurizio Scaltriti, Alexander Drilon, Alexia Iasonos, Barry S. Taylor, David M. Hyman
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (12_Supplement_1): 16.
https://doi.org/10.1158/1557-3265.ADVPRECMED20-16
Published: 15 June 2020
View articletitled, Abstract 16: Landscape and outcome of TRK fusion-positive Cancers
Journal Articles

TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations

Free
Ezra Y. Rosen, Debra A. Goldman, Jaclyn F. Hechtman, Ryma Benayed, Alison M. Schram, Emiliano Cocco, Sophie Shifman, Yixiao Gong, Ritika Kundra, James P. Solomon, Alberto Bardelli, Maurizio Scaltriti, Alexander Drilon, Alexia Iasonos, Barry S. Taylor, David M. Hyman
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (7): 1624–1632.
https://doi.org/10.1158/1078-0432.CCR-19-3165
Published: 01 April 2020
View articletitled, TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations
Open the PDF for TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations in another window
Includes: Supplementary data
Journal Articles

Abstract 61: Overcoming acquired resistance to PI3K inhibitors in head and neck squamous cell carcinoma with combination treatment

Free
Aviram Mizrachi, Lara Dunn, Alan Ho, Maurizio Scaltriti
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (23_Supplement): 61.
https://doi.org/10.1158/1557-3265.AACRAHNS17-61
Published: 30 November 2017
View articletitled, Abstract 61: Overcoming acquired resistance to PI3K inhibitors in head and neck squamous cell carcinoma with combination treatment
Journal Articles

Abstract IA22: Studying drug resistance through PDX models

Free
Maurizio Scaltriti
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (16_Supplement): IA22.
https://doi.org/10.1158/1557-3265.PDX16-IA22
Published: 15 August 2016
View articletitled, Abstract IA22: Studying drug resistance through PDX models
Journal Articles

Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations

Free
Zachary S. Zumsteg, Natasha Morse, Gabriel Krigsfeld, Gaorav Gupta, Daniel S. Higginson, Nancy Y. Lee, Luc Morris, Ian Ganly, Stephan L. Shiao, Simon N. Powell, Christine H. Chung, Maurizio Scaltriti, José Baselga
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (8): 2009–2019.
https://doi.org/10.1158/1078-0432.CCR-15-2245
Published: 14 April 2016
View articletitled, Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations
Open the PDF for Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations in another window
Includes: Supplementary data
Journal Articles

Molecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to Therapy

Free
Maurizio Scaltriti, Moshe Elkabets, José Baselga
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (6): 1313–1317.
https://doi.org/10.1158/1078-0432.CCR-15-1458
Published: 14 March 2016
View articletitled, Molecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to Therapy
Open the PDF for Molecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to Therapy in another window
Journal Articles

MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer

Free
Celina García-García, Martín A. Rivas, Yasir H. Ibrahim, María Teresa Calvo, Albert Gris-Oliver, Olga Rodríguez, Judit Grueso, Pilar Antón, Marta Guzmán, Claudia Aura, Paolo Nuciforo, Katti Jessen, Guillem Argilés, Rodrigo Dienstmann, Andrea Bertotti, Livio Trusolino, Judit Matito, Ana Vivancos, Irene Chicote, Héctor G. Palmer, Josep Tabernero, Maurizio Scaltriti, José Baselga, Violeta Serra
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2015) 21 (24): 5499–5510.
https://doi.org/10.1158/1078-0432.CCR-14-3091
Published: 14 December 2015
View articletitled, MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer
Open the PDF for MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

High HER2 Expression Correlates with Response to the Combination of Lapatinib and Trastuzumab

Free
Maurizio Scaltriti, Paolo Nuciforo, Ian Bradbury, Jeff Sperinde, Dominique Agbor-Tarh, Christine Campbell, Ahmed Chenna, John Winslow, Violeta Serra, Josep Lluis Parra, Ludmila Prudkin, José Jimenez, Claudia Aura, Nadia Harbeck, Lajos Pusztai, Catherine Ellis, Holger Eidtmann, Joaquin Arribas, Javier Cortes, Evandro de Azambuja, Martine Piccart, José Baselga
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2015) 21 (3): 569–576.
https://doi.org/10.1158/1078-0432.CCR-14-1824
Published: 01 February 2015
View articletitled, High HER2 Expression Correlates with Response to the Combination of Lapatinib and Trastuzumab
Open the PDF for High HER2 Expression Correlates with Response to the Combination of Lapatinib and Trastuzumab in another window
Includes: Supplementary data
Journal Articles

Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068

Free
Yibing Yan, Violeta Serra, Ludmila Prudkin, Maurizio Scaltriti, Sumati Murli, Olga Rodríguez, Marta Guzman, Deepak Sampath, Michelle Nannini, Yuanyuan Xiao, Marie-Claire Wagle, Jenny Q. Wu, Matthew Wongchenko, Garret Hampton, Vanitha Ramakrishnan, Mark R. Lackner, Cristina Saura, Desamparados Roda, Andrés Cervantes, Josep Tabernero, Premal Patel, José Baselga
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2013) 19 (24): 6976–6986.
https://doi.org/10.1158/1078-0432.CCR-13-0978
Published: 16 December 2013
View articletitled, Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068
Open the PDF for Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068 in another window
Includes: Supplementary data
Journal Articles

Molecular Pathways: Targeting Hsp90—Who Benefits and Who Does Not

Free
Maurizio Scaltriti, Shaheenah Dawood, Javier Cortes
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (17): 4508–4513.
https://doi.org/10.1158/1078-0432.CCR-11-2138
Published: 30 August 2012
View articletitled, Molecular Pathways: Targeting Hsp90—Who Benefits and Who Does Not
Open the PDF for Molecular Pathways: Targeting Hsp90—Who Benefits and Who Does Not in another window
Journal Articles

Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy

Free
Celina García-García, Yasir H. Ibrahim, Violeta Serra, Maria Teresa Calvo, Marta Guzmán, Judit Grueso, Claudia Aura, José Pérez, Katti Jessen, Yi Liu, Christian Rommel, Josep Tabernero, José Baselga, Maurizio Scaltriti
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (9): 2603–2612.
https://doi.org/10.1158/1078-0432.CCR-11-2750
Published: 30 April 2012
View articletitled, Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy
Open the PDF for Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy in another window
Includes: Supplementary data
Journal Articles

Clinical Benefit of Lapatinib-Based Therapy in Patients with Human Epidermal Growth Factor Receptor 2–Positive Breast Tumors Coexpressing the Truncated p95HER2 Receptor

Free
Maurizio Scaltriti, Sarat Chandarlapaty, Ludmila Prudkin, Claudia Aura, José Jimenez, Pier Davide Angelini, Gertrudis Sánchez, Marta Guzman, Josep Lluis Parra, Catherine Ellis, Robert Gagnon, Maria Koehler, Henry Gomez, Charles Geyer, David Cameron, Joaquin Arribas, Neal Rosen, José Baselga
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (9): 2688–2695.
https://doi.org/10.1158/1078-0432.CCR-09-3407
Published: 28 April 2010
View articletitled, Clinical Benefit of Lapatinib-Based Therapy in Patients with Human Epidermal Growth Factor Receptor 2–Positive Breast Tumors Coexpressing the Truncated p95HER2 Receptor
Open the PDF for Clinical Benefit of Lapatinib-Based Therapy in Patients with Human Epidermal Growth Factor Receptor 2–Positive Breast Tumors Coexpressing the Truncated p95HER2 Receptor in another window
Includes: Supplementary data
Journal Articles

Loss of HER2 Amplification Following Trastuzumab-Based Neoadjuvant Systemic Therapy and Survival Outcomes

Free
Elizabeth A. Mittendorf, Yun Wu, Maurizio Scaltriti, Funda Meric-Bernstam, Kelly K. Hunt, Shaheenah Dawood, Francisco J. Esteva, Aman U. Buzdar, Huiqin Chen, Sameena Eksambi, Gabriel N. Hortobagyi, Jose Baselga, Ana M. Gonzalez-Angulo
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (23): 7381–7388.
https://doi.org/10.1158/1078-0432.CCR-09-1735
Published: 30 November 2009
View articletitled, Loss of HER2 Amplification Following Trastuzumab-Based Neoadjuvant Systemic Therapy and Survival Outcomes
Open the PDF for Loss of HER2 Amplification Following Trastuzumab-Based Neoadjuvant Systemic Therapy and Survival Outcomes in another window
Journal Articles

The Epidermal Growth Factor Receptor Pathway: A Model for Targeted Therapy

Free
Maurizio Scaltriti, José Baselga
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (18): 5268–5272.
https://doi.org/10.1158/1078-0432.CCR-05-1554
Published: 25 September 2006
View articletitled, The Epidermal Growth Factor Receptor Pathway: A Model for Targeted Therapy
Open the PDF for The Epidermal Growth Factor Receptor Pathway: A Model for Targeted Therapy in another window